The startup provides transparent AI technology that enhances tissue-based diagnostics and prognostics in computational pathology. By integrating with existing workflows, it improves disease treatment efficiency in clinical and pharmaceutical settings, enabling personalized medicine through effective AI utilization.
Funding
$710K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Pathologists face increasing workloads and staff shortages, leading to potential delays and variability in tissue-based diagnostics, particularly in the analysis of gastrointestinal (GI) biopsies and the quantification of mitotic figures in cancer grading. Manual analysis is time-consuming and prone to inter-observer variability, hindering efficient and accurate disease assessment.
Solution
Histofy provides AI-powered solutions for computational pathology, enhancing tissue-based diagnostics and prognostics. Their suite of tools integrates with existing clinical workflows to streamline pathology, reduce turnaround times, and improve the accuracy and efficiency of reporting. Histofy's technology leverages pixel data from digital pathology images to provide interpretable numerical features, enabling precise disease profiling, patient stratification, and biomarker discovery. The AI algorithms identify key histological structures and cells, transforming complex image data into measurable attributes that support better patient care and advancements in biopharma research.
Target Audience
Histofy's primary customers include pathologists, biomedical researchers, and pharmaceutical companies seeking to improve the efficiency, accuracy, and depth of tissue image analysis for enhanced diagnostics, prognostics, and drug development.
Features
- AI-powered colon biopsy screening to filter out normal slides, reducing pathologist workload
- MitPro®: AI-driven algorithm for precise mitosis quantification and profiling across various cancer types
- GI-Miner: Suite of tools for deep cellular and multi-cellular analysis of GI tissue, generating measurable attributes for pathology (MAPs)
- Identification and delineation of glands, lumen, nuclei, goblet cells, and signet ring cells
- Semantic segmentation of over 15 key tissue types in large bowel
- Customizable feature list for assessing disease severity and response to treatment
- Seamless integration with existing pathology image management systems
- Transparent AI predictions for trustworthy decision support